2020 MELANOMA – POSTOW – Understanding Immunotherapy Resistance Mechanisms in Melanoma

2020 MELANOMA – POSTOW – Understanding Immunotherapy Resistance Mechanisms in Melanoma

Publication date: Feb 10, 2021

GRACE is excited to bring you a new series on current updates in Melanoma Treatment. Meredith McKean MD, MPH with Tennessee Oncology, Michael Postow, MD Chief of Melanoma Service at Memorial Sloan Kettering, and Sanjiv Agarwala, MD, Professor of Medical Oncology and Hematology at Temple University School of Medicine in Easton, PA joined GRACE to discuss current updates in treatment for Melanoma. In this video, Dr. Postow discusses understanding immunotherapy resistance mechanisms in melanoma. A huge thank you to Merck for sponsoring this program. For more, please visit http://cancerGRACE. org/. To join the conversation, visit https://cancergrace. org/forum.

Concepts Keywords
Air Immunotherapy
Antigens Surface melanoma tumor
Biomarker Standard melanoma
Biomarkers Case tumors
Biopsies Response melanoma tumor
Biopsy Melanoma tumors
Easton High tumor
Energon Melanomas
Europe Drug reason melanoma
GRACE Immune therapy melanoma
Hematology Tumor
Immune Response Melanoma care
Immune System Melanoma Treatment
Immunotherapy Medicine
Kettering Clinical medicine
Melanoma Cancer treatments
Melanomas Melanoma
Merck Antineoplastic drugs
Mountain Immunotherapy
Mutation Immune system
Oncology Targeted therapy
Perfectly Black Cancer immunotherapy
PTL Uveal melanoma
Targeted Therapy Http
Tennessee
Tumor

Semantics

Type Source Name
disease MESH MELANOMA
pathway KEGG Melanoma
drug DRUGBANK Methylphenidate
disease MESH Cancer
drug DRUGBANK Nonoxynol-9
drug DRUGBANK Medical air
disease MESH biopsy
pathway REACTOME Immune System
drug DRUGBANK Tropicamide
disease MESH death
drug DRUGBANK Water
pathway KEGG Antigen processing and presentation

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *